Martin et al, Long-term clinical and safety outcomes from a single-site phase 1 study of neural stem cell transplantation for chronic thoracic spinal cord injury, Cell Reports Medicine (2024).

these progenitor cells lose their regenerative potential, making adult spinal cord tissue less capable of recovery after injury. Identifying endogenous stem cells with diverse lineage potentials ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

More than 15 million people worldwide are living with spinal cord injury (SCI), which can affect their sensory and motor ...

works by "fusing" the membranes of damaged nerve cells, and it can be applied up to eight hours after the injury without adversely affecting the patient's recovery. The process may someday be used in ...

Nerve cells in the spinal cord do not regenerate easily and scar tissue forms quickly ... and improving recovery. Shortly after the injury, steroid medications and surgery are used to help reduce ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...